Quest for the right Drug

|
עמוד הבית / אינסולטרד ויאל / מידע מעלון לרופא

אינסולטרד ויאל INSULATARD VIAL (INSULIN (HUMAN))

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תת-עורי : S.C

צורת מינון:

תרחיף להזרקה : SUSPENSION FOR INJECTION

Posology : מינונים

4.2    Posology and method of administration

Posology
The potency of human insulin is expressed in international units.

Insulatard dosing is individual and determined in accordance with the needs of the patient. The physician determines whether one or several daily injections are necessary. Insulatard may be used alone or mixed with fast-acting insulin. In intensive insulin therapy the suspension may be used as basal insulin (evening and/or morning injection) with fast-acting insulin given at meals. Blood glucose monitoring is recommended to achieve optimal glycaemic control.

The individual insulin requirement is usually between 0.3 and 1.0 international unit/kg/day.

Adjustment of dose may be necessary if patients undertake increased physical activity, change their usual diet or during concomitant illness.

Special populations

Elderly (≥ 65 years old)
Insulatard can be used in elderly patients.
In elderly patients, glucose monitoring should be intensified and the insulin dose adjusted on an individual basis.

Renal and hepatic impairment
Renal or hepatic impairment may reduce the patient’s insulin requirements.
In patients with renal or hepatic impairment, glucose monitoring should be intensified and the human insulin dose adjusted on an individual basis.

Paediatric population
Insulatard can be used in children and adolescents.

Transfer from other insulin medicinal products
When transferring from other intermediate or long-acting insulin medicinal products, adjustment of the Insulatard dose and timing of administration may be necessary.

Close glucose monitoring is recommended during the transfer and in the initial weeks thereafter (see section 4.4).

Method of administration

Insulatard is a human insulin with gradual onset and long duration of action.
Insulatard is administered subcutaneously by injection in the thigh, the abdominal wall, the gluteal region or the deltoid region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see sections 4.4 and 4.8). Insulin suspensions are never to be administered intravenously. Injection into a lifted skin fold minimises the risk of unintended intramuscular injection.

The needle should be kept under the skin for at least 6 seconds to make sure the entire dose is injected.
Subcutaneous injection into the thigh results in a slower and less variable absorption compared to the other injection sites. The duration of action will vary according to the dose, injection site, blood flow, temperature and level of physical activity.

Insulin suspensions are not to be used in insulin infusion pumps.

For detailed user instructions, please refer to the package leaflet.
Insulatard vial (100 international units/ml)
Administration with a syringe
Insulatard vials are for use with insulin syringes with a corresponding unit scale.

Insulatard Penfill
Administration with an insulin delivery system
Insulatard Penfill is designed to be used with Novo Nordisk insulin delivery systems and NovoFine or NovoTwist needles. Insulatard Penfill is only suitable for subcutaneous injections from a reusable pen.
If administration by syringe is necessary, a vial should be used.


שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

NOVO NORDISK LTD., ISRAEL

רישום

049 88 26013 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

18.01.21 - עלון לרופא

עלון מידע לצרכן

20.07.21 - עלון לצרכן אנגלית 20.07.21 - עלון לצרכן עברית 20.07.21 - עלון לצרכן ערבית 18.01.21 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אינסולטרד ויאל

קישורים נוספים

RxList WebMD Drugs.com